8a56fc651e6c719e9a7ef7747b.GWgO1nKOMleGZRSiGXwInWeB8VaJK0C9AMS21GNwNHU.VVpklyj3ZSHwIXbXbzYxriX4wiX6EwXbcq_zlloyBg9VDm-zALpCAtUPfw
14/11 Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products BU
14/11 Zai Lab Announces Participation in Investor Conferences in November 2026 BU
14/11 Zai Lab Limited - Special Call
13/11 Zai Lab Says Experimental Drug Reduced Activity of Protein Linked to Atopic Dermatitis by at Least 90% MT
13/11 Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing BU
09/11 Zai Lab Limited announced that it has received $249.9336 million in funding from a group of investors CI
07/11 Zai Lab Q3 Performance Meets Expectations With Pivotal 2027 Ahead, UBS Says MT
06/11 Zai Lab Q3 Loss Widens, Revenue Declines MT
06/11 Zai Lab Limited, Q3 2026 Earnings Call, Nov 05, 2026
06/11 Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas BU
06/11 Zai Lab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
05/11 Earnings Flash (ZLAB) Zai Lab Limited Reports Q3 Revenue $108.2M, vs. FactSet Est of $107.9M MT
05/11 Earnings Flash (ZLAB) Zai Lab Limited Reports Q3 Revenue $108.2M, vs. FactSet Est of $107.9M MT
05/11 Earnings Flash (ZLAB) Zai Lab Limited Reports Q3 Loss of $0.41 per ADS, vs. FactSet Est of $-0.58 MT
05/11 Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates BU
27/10 Zai Lab Limited announced that it has received $249.9336 million in funding CI
26/10 Zai Lab's Lung Cancer Drug Achieves Promising Response Rate in Phase 1b Trial; Shares up 4% MT
24/10 Zai Lab Limited - Special Call
23/10 Zai Lab Says Zoci Plus Atezolizumab Improves Response Rate in Phase 1 Lung Cancer Trial MT
23/10 Zai Lab Limited Shares First Data From Global Phase 1b Clinical Trial Evaluating Zocilurtatug Pelitecan In Combination With Atezolizumab With And Without Carboplatin As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer CI
23/10 Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer BU
23/10 Zai Lab to Privately Place $250 Million in ADRs to Fund Drug Research MT
23/10 Zai Lab to Raise $250 Million in Private Placement of ADSs MT
23/10 Zai Lab Announces $250 Million Private Placement BU
22/10 Zai Lab Limited announced that it expects to receive $249.9336 million in funding CI

Become a member to access more news

New member
No results match your criteria
  1. Stock Market
  2. Stocks
  3. ZLAB Stock
  4. News Zai Lab Limited